Xeris Biopharma Holdings annual free cash flow per share
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Free Cash Flow Per Share Growth & History (XERS)
Xeris Biopharma Holdings's free cash flow per share was $0.17 for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.17 | $0.43 | — |
| 2024 | 2024-12-31 | -$0.26 | $0.10 | — |
| 2023 | 2023-12-31 | -$0.36 | $0.40 | — |
| 2022 | 2022-12-31 | -$0.76 | $0.46 | — |
| 2021 | 2021-12-31 | -$1.22 | $0.68 | — |
| 2020 | 2020-12-31 | -$1.90 | — | — |
Xeris Biopharma Holdings quarterly free cash flow per share
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.05 | $0.05 | — |
| Q1 2026 | 2026-03-31 | $0.06 | — | — |
| Q4 2025 | 2025-12-31 | $0.12 | — | — |
| Q3 2025 | 2025-09-30 | $0.11 | — | — |
| Q2 2025 | 2025-06-30 | -$0.00 | — | — |
Xeris Biopharma Holdings free cash flow per share trends
Over the last five fiscal years, Xeris Biopharma Holdings's free cash flow per share increased from -$1.90 to $0.17, a change of $2.07. The latest reported quarter, Q2 2026, shows $0.05.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗